glp-1 agonist in esrd CKJ REVIEW receptor agonists patients with chronic kidney disease and either overweight or obesit Recommendations for SGLT2i versus GLP-1
Description
Tools like InBody or DEXA scans can be helpful for monitoring body composition and supporting long-term health outcomes
These effects can lead to dehydration, electrolyte imbalances, or reduced nutrient absorption
Other side effects can include dizziness, headache, and increased heart rate
Retrospective studies are inconsistent
We would look forward to changing this if safety evidence emerges
